Literature DB >> 8625661

Spirometry and dyspnea in patients with COPD. When small differences mean little.

D A Redelmeier1, R S Goldstein, S T Min, R H Hyland.   

Abstract

OBJECTIVE: To determine when a difference in FEV1 is sufficiently large to be associated with a noticeable difference in dyspnea symptoms for patients with chronic lung disease.
DESIGN: Cross-sectional analysis of 15 groups (n = 112 patients, 832 contrasts).
SETTING: Respiratory rehabilitation program. PATIENTS: Patients with COPD (mean FEV1 = 35% predicted). MEASURES: Patients' perspectives assessed through subjective comparison ratings of dyspnea and of overall health. Relation between the FEV1 and patients' perspectives determined the smallest difference in spirometry that was associated with a noticeable difference in patients' symptoms.
RESULTS: The FEV1 was moderately correlated with patients' ratings of dyspnea (r = 0.29; 95% confidence interval (CI), 0.22 to 0.35). In contrast, the FEV1 was minimally correlated with patients' ratings of overall health (r = 0.10; 95% CI, 0.03 to 0.17). The FEV1 needed to differ by 4% predicted for the average patient to stop rating his or her dyspnea as "about the same" and start rating his or her dyspnea as either "a little bit better" or "a little bit worse" relative to other patients (95% CI, 1.5 to 6.5). This was equivalent to the average patient's FEV1 increasing by 112 mL (starting from 975 mL and ending at 1,087 mL).
CONCLUSIONS: Some statistically significant differences in the FEV1 are so small that they may not represent important differences in symptoms for the average patient with severe COPD; an awareness of the smallest difference in FEV1 that is noticeable to patients can help clinicians interpret the effectiveness of symptomatic treatments.

Entities:  

Mesh:

Year:  1996        PMID: 8625661     DOI: 10.1378/chest.109.5.1163

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  21 in total

1.  Estimating clinically significant differences in quality of life outcomes.

Authors:  Kathleen W Wyrwich; Monika Bullinger; Neil Aaronson; Ron D Hays; Donald L Patrick; Tara Symonds
Journal:  Qual Life Res       Date:  2005-03       Impact factor: 4.147

Review 2.  Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?

Authors:  Matthew C Miles; James F Donohue; Jill A Ohar
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

3.  ARTP statement on pulmonary function testing 2020.

Authors:  Karl Peter Sylvester; Nigel Clayton; Ian Cliff; Michael Hepple; Adrian Kendrick; Jane Kirkby; Martin Miller; Alan Moore; Gerrard Francis Rafferty; Liam O'Reilly; Joanna Shakespeare; Laurie Smith; Trefor Watts; Martyn Bucknall; Keith Butterfield
Journal:  BMJ Open Respir Res       Date:  2020-07

Review 4.  Dyspnoea in the elderly: a clinical approach to diagnosis.

Authors:  J C Yernault
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Problems for clinical judgement: 1. Eliciting an insightful history of present illness.

Authors:  D A Redelmeier; M J Schull; J E Hux; J V Tu; L E Ferris
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

6.  Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.

Authors:  Mario Cazzola; Pierluigi Paggiaro; Paolo Palange; Leif Bjermer; Pilar Ausin; Lars-Goran Carlsson; Jan Ekelund; Jan Lotvall
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

Review 7.  Pulmonary rehabilitation in emphysema.

Authors:  Andrew L Ries; Barry J Make; John J Reilly
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

8.  Influence of lung volume reduction surgery (LVRS) on health related quality of life in patients with chronic obstructive pulmonary disease.

Authors:  R S Goldstein; T R J Todd; G Guyatt; S Keshavjee; T E Dolmage; S van Rooy; B Krip; F Maltais; P LeBlanc; S Pakhale; T K Waddell
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

9.  Variability of spirometry in chronic obstructive pulmonary disease: results from two clinical trials.

Authors:  Laura B Herpel; Richard E Kanner; Shing M Lee; Henry E Fessler; Frank C Sciurba; John E Connett; Robert A Wise
Journal:  Am J Respir Crit Care Med       Date:  2006-02-23       Impact factor: 21.405

10.  Implementation of British Thoracic Society guidelines for acute exacerbation of chronic obstructive pulmonary disease: impact on quality of life.

Authors:  K Dheda; A Crawford; G Hagan; C M Roberts
Journal:  Postgrad Med J       Date:  2004-03       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.